Integrated clinical and single-cell profiling of BCMA CAR-T therapy in relapsed/refractory multiple myeloma.

ABSTRACT:

Background

Despite therapeutic advances, multiple myeloma (MM) remains incurable, especially in relapsed/refractory (R/R) disease. B-cell maturation antigen (BCMA)-targeted CAR-T therapy, exemplified by FDA-approved agents like ide-cel and cilta-cel, offers promise, yet accessibility barriers necessitate local production.

Methods

This single-arm trial evaluated safety/efficacy of autologous BCMA CAR-T cells in six R/R MM patients.

Results

Cytokine release syndrome (CRS) occurred in 83% (grade 1), managed with tocilizumab without neurotoxicity. Toxicities were transient and resolved. Serum cytokine (IFN-γ, IL-6/8/10) peaked during CRS. Responses included 83% overall response (67% stringent complete response), unaffected by extramedullary disease or high-risk cytogeneti

SUBMITTER: Fang C 

PROVIDER: S-EPMC12604393 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature